Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
VMF
0
Canada
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. Ferinject
2. Injectafer
3. Iron Carboxymaltose
4. Iron Dextri-maltose
5. Polynuclear Iron (iii)-hydroxide 4(r)-(poly-(1->4)-o-alpha-d-glucopyranosyl)-oxy-2(r),3(s),5(r), 6-tetrahydroxy-hexanoate
6. Vit 45
7. Vit-45
1. 9007-72-1
2. Ex-a3450
3. (2s,3s,4s,5r)-4-[(2r,3r,4r,5s,6r)-5-[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanoate;iron(3+);oxygen(2-);hydroxide;hydrate
Molecular Weight | 788.4 g/mol |
---|---|
Molecular Formula | C24H44FeO25- |
Hydrogen Bond Donor Count | 16 |
Hydrogen Bond Acceptor Count | 25 |
Rotatable Bond Count | 13 |
Exact Mass | 788.152102 g/mol |
Monoisotopic Mass | 788.152102 g/mol |
Topological Polar Surface Area | 382 Ų |
Heavy Atom Count | 50 |
Formal Charge | -1 |
Complexity | 940 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 19 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 5 |
1 of 2 | |
---|---|
Drug Name | Injectafer |
PubMed Health | ferric carboxymaltose |
Drug Classes | Iron Supplement |
Drug Label | Ferric carboxymaltose, an iron replacement product, is an iron carbohydrate complex with the chemical name of polynuclear iron (III) hydroxide 4(R)-(poly-(14)-O--D-glucopyranosyl)-oxy-2(R),3(S),5(R),6-tetrahydroxy-hexanoate. It has a relative mo... |
Active Ingredient | Ferric carboxymaltose |
Dosage Form | Injectable |
Route | Intravenous |
Strength | 750mg iron/15ml (50mg iron/ml) |
Market Status | Prescription |
Company | Luitpold |
Patent | 7612109; 7754702 |
2 of 2 | |
---|---|
Drug Name | Injectafer |
PubMed Health | ferric carboxymaltose |
Drug Classes | Iron Supplement |
Drug Label | Ferric carboxymaltose, an iron replacement product, is an iron carbohydrate complex with the chemical name of polynuclear iron (III) hydroxide 4(R)-(poly-(14)-O--D-glucopyranosyl)-oxy-2(R),3(S),5(R),6-tetrahydroxy-hexanoate. It has a relative mo... |
Active Ingredient | Ferric carboxymaltose |
Dosage Form | Injectable |
Route | Intravenous |
Strength | 750mg iron/15ml (50mg iron/ml) |
Market Status | Prescription |
Company | Luitpold |
Patent | 7612109; 7754702 |
Ferric carboxymaltose is a iron replacement product indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron or those who have non-dialysis dependent chronic kidney disease.
FDA Label
When measured using positron emission tomography (PET), the red cell uptake of 59-Fe and 52-Fe from INJECTAFER ranged from 61% to 99%. In patients with iron deficiency, the red cell uptake ranged from 91% to 99%. In patients with renal anemia, the red cell uptake ranged from 61% to 84%.
Absorption
When a single dose of 100 to 1000 mg of iron was given to iron deficient patients, the maximum serum concentration (Cmax) was 37 g/mL to 333 g/mL. These levels were obtained 15 minutes to 1.21 hours post dose (Tmax).
Route of Elimination
Renal elimination of iron was negligible.
Volume of Distribution
3 L
7 to 12 hours.
Ferric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that release iron.
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38006
Submission : 2024-07-17
Status : Active
Type : II
NDC Package Code : 64552-4070
Start Marketing Date : 2013-07-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : ASMF |
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-10-18
Pay. Date : 2023-07-06
DMF Number : 38204
Submission : 2023-03-29
Status : Active
Type : II
NDC Package Code : 71796-054
Start Marketing Date : 2023-03-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-09-10
Pay. Date : 2018-08-13
DMF Number : 33038
Submission : 2018-08-02
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39631
Submission : 2024-03-18
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-10-05
Pay. Date : 2023-08-29
DMF Number : 35529
Submission : 2023-03-24
Status : Active
Type : II
NDC Package Code : 69766-093
Start Marketing Date : 2023-03-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-06-19
Pay. Date : 2018-05-02
DMF Number : 32437
Submission : 2018-03-29
Status : Active
Type : II
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38006
Submission : 2024-07-17
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2023-10-18
Pay. Date : 2023-07-06
DMF Number : 38204
Submission : 2023-03-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36795
Submission : 2022-03-10
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37389
Submission : 2022-07-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-05-04
Pay. Date : 2023-02-24
DMF Number : 38062
Submission : 2023-02-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35442
Submission : 2020-12-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39631
Submission : 2024-03-18
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-06-19
Pay. Date : 2018-05-02
DMF Number : 32437
Submission : 2018-03-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-10-05
Pay. Date : 2023-08-29
DMF Number : 35529
Submission : 2023-03-24
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-09-10
Pay. Date : 2018-08-13
DMF Number : 33038
Submission : 2018-08-02
Status : Active
Type : II
Registration Number : 229MF10211
Registrant's Address : Rechenstrasse 37, CH-9001 St. Gallen
Initial Date of Registration : 2017-12-01
Latest Date of Registration : 2023-10-04
Registrant Name : Otran Pharm Korea Co., Ltd.
Registration Date : 2024-02-29
Registration Number : 20240229-211-J-1614
Manufacturer Name : BrightGene Fine Chemical Co....
Manufacturer Address : No. 10 Tongyuan Road, Taixing Economic Development Zone, Taizhou, Jiangsu 225400, Chi...
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
About the Company : Interquim, founded in 1978, is now part of the Ferrer HealthTech division. Interquim specializes in the development of competitive processes for manufacturing high added-value APIs...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
About the Company : Specializing in natural & oncology APIs, we establish R&D and production platforms for new salt, crystal form & synthetic biology research. We cooperate with clients for IND, NDA, ...
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...
About the Company : Lee helps you focus on the business results that matter to your company. Over the years, we have leveraged our position in the global market with an enviable list of clients and a ...
About the Company : Huiyu Pharma, established in Oct. 2010, is a specialized pharmaceutical company focusing on developing and manufacturing high-quality oncology products. At present, products in our...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Ferinject (ferric carboxymaltose) is an approved small molecule Fe modulator for treating iron deficiency anemia in patients aged one year and older when oral iron is not tolerated.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Brand Name: Ferinject
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ferinject® Approved by Health Canada for Iron Deficiency Anemia in Adults and Pediatrics
Details : Ferinject (ferric carboxymaltose) is an approved small molecule Fe modulator for treating iron deficiency anemia in patients aged one year and older when oral iron is not tolerated.
Brand Name : Ferinject
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 19, 2024
Details:
Ferinject (ferric carboxymaltose) is an iron replacement medicine, used to treat a type of anemia where you have fewer amount of red blood cells due to insufficient iron in your body. Iron is needed to produce the red blood cells that carry oxygen around your body.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Brand Name: Ferinject
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ferinject® Granted Upgraded Recommendations in 2023 ESC Heart Failure Guidelines
Details : Ferinject (ferric carboxymaltose) is an iron replacement medicine, used to treat a type of anemia where you have fewer amount of red blood cells due to insufficient iron in your body. Iron is needed to produce the red blood cells that carry oxygen around...
Brand Name : Ferinject
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 28, 2023
Details:
Injectafer (ferric carboxymaltose injection) is indicated for the improvement of exercise capacity for iron deficient adult patients with symptomatic heart failure; iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Brand Name: Injectafer
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2023
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
American Regent Announces Results From Phase 3 HEART-FID Trial with INJECTAFER®
Details : Injectafer (ferric carboxymaltose injection) is indicated for the improvement of exercise capacity for iron deficient adult patients with symptomatic heart failure; iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older.
Brand Name : Injectafer
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 26, 2023
Details:
Injectafer (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency in adult patients with iron deficiency in adult patients with heart failure categorized.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Brand Name: Injectafer
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: American Regent
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : American Regent
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Injectafer (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency in adult patients with iron deficiency in adult patients with heart failure categorized.
Brand Name : Injectafer
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 05, 2023
Details:
Orofer (ferric carboxymaltose) which is capable of releasing iron, helping in the synthesis of haemoglobin and increases red blood cell count. As a result, it treats iron deficiency anaemia.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Brand Name: Orofer
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Emcure Pharmaceuticals to Launch The 750 Mg Injectable Variant of Ferric Carboxymaltose
Details : Orofer (ferric carboxymaltose) which is capable of releasing iron, helping in the synthesis of haemoglobin and increases red blood cell count. As a result, it treats iron deficiency anaemia.
Brand Name : Orofer
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 17, 2023
Details:
Ferinject 50mg/ml Solution for Injection is an iron replacement medicine, used to treat a type of anemia where you have fewer amount of red blood cells due to insufficient iron in your body. Iron is needed to produce the red blood cells that carry oxygen around your body.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Brand Name: Ferinject
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ferinject® Approved In Chinafor The Treatment Of Iron Deficiency In Adult Patients
Details : Ferinject 50mg/ml Solution for Injection is an iron replacement medicine, used to treat a type of anemia where you have fewer amount of red blood cells due to insufficient iron in your body. Iron is needed to produce the red blood cells that carry oxygen...
Brand Name : Ferinject
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 28, 2022
Details:
CSL Limited acquire Vifor Pharma's therapeutic segment of iron deficiency, nephrology and cardio-renal therapies containing Venofer® and Maltofer® and strategic growth driver Ferinject®/Injectafer® (ferric carboxymaltose).
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Brand Name: Ferinject
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: CSL
Deal Size: $11,700.0 million Upfront Cash: $11,700.0 million
Deal Type: Acquisition August 02, 2022
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : CSL
Deal Size : $11,700.0 million
Deal Type : Acquisition
Finalization of Vifor Pharma Acquisition
Details : CSL Limited acquire Vifor Pharma's therapeutic segment of iron deficiency, nephrology and cardio-renal therapies containing Venofer® and Maltofer® and strategic growth driver Ferinject®/Injectafer® (ferric carboxymaltose).
Brand Name : Ferinject
Molecule Type : Small molecule
Upfront Cash : $11,700.0 million
August 02, 2022
Details:
CSL Limited acquire Vifor Pharma's therapeutic segment of iron deficiency, nephrology and cardio-renal therapies containing Venofer® and Maltofer® and strategic growth driver Ferinject®/Injectafer® (ferric carboxymaltose).
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Brand Name: Ferinject
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: CSL
Deal Size: $11,700.0 million Upfront Cash: $11,700.0 million
Deal Type: Acquisition December 14, 2021
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : CSL
Deal Size : $11,700.0 million
Deal Type : Acquisition
CSL Limited Announces Tender Offer to Acquire Vifor Pharma Ltd
Details : CSL Limited acquire Vifor Pharma's therapeutic segment of iron deficiency, nephrology and cardio-renal therapies containing Venofer® and Maltofer® and strategic growth driver Ferinject®/Injectafer® (ferric carboxymaltose).
Brand Name : Ferinject
Molecule Type : Small molecule
Upfront Cash : $11,700.0 million
December 14, 2021
Details:
The U.S FDA has approved a single 1000 mg dose option of Injectafer®, ferric carboxymaltose injection, an iron replacement product, for iron deficiency anemia patients who have intolerance to oral iron, have low response to oral iron, or have non-dialysis dependent CKD.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Brand Name: Injectafer
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: M.D. Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : M.D. Anderson Cancer Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Daiichi Sankyo's Injectafer® Receives FDA Approval for Single Dose Option for the Treatment of Ad...
Details : The U.S FDA has approved a single 1000 mg dose option of Injectafer®, ferric carboxymaltose injection, an iron replacement product, for iron deficiency anemia patients who have intolerance to oral iron, have low response to oral iron, or have non-dialys...
Brand Name : Injectafer
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 06, 2021
Details:
The study demonstrated there were significantly fewer hospital readmissions due to HF among patients treated with Ferinject® compared to placebo.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Ferinject
Study Phase: Phase IVProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vifor Pharma's AFFIRM-AHF Study Show Ferinject® Reduces Hospitalizations After Acute Heart Failur...
Details : The study demonstrated there were significantly fewer hospital readmissions due to HF among patients treated with Ferinject® compared to placebo.
Brand Name : Ferinject
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 13, 2020
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 50MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Ferinject
Dosage Form : INJ
Dosage Strength : 50mg/ml
Packaging : 10X1mg/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : USA
Registration Country : Greece
Brand Name :
Dosage Form : Solution for Injection/Infusion
Dosage Strength : 100MG/2ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : USA
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : USA
Registration Country : Greece
Brand Name :
Dosage Form : Solution for Injection/Infusion
Dosage Strength : 500MG/10ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : USA
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : USA
Registration Country : Greece
Brand Name :
Dosage Form : Solution for Injection/Infusion
Dosage Strength : 750MG/15ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : USA
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : USA
Registration Country : Greece
Brand Name :
Dosage Form : Solution for Injection/Infusion
Dosage Strength : 1000MG/20ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : USA
Registration Country : Greece
Regulatory Info : RX
Registration Country : USA
Brand Name : INJECTAFER
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 500MG IRON/10ML (50MG IRON/ML)
Packaging :
Approval Date : 2020-10-08
Application Number : 203565
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Vial
Dosage Strength : 50MG/ML
Packaging : 10 ml, 15 ml
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : Italy
Brand Name : Ferinject
Dosage Form : Ferric Carbossimaltosio 50Mg/Ml 10Ml 1 Units Parenteral Use
Dosage Strength : 1 vial EV 10 ml 50 mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 50MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
RLD : Yes
TE Code :
Brand Name : INJECTAFER
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 750MG IRON/15ML (50MG IRON/ML)
Approval Date : 2013-07-25
Application Number : 203565
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : INJECTAFER
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 500MG IRON/10ML (50MG IRON/ML)
Approval Date : 2020-10-08
Application Number : 203565
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : INJECTAFER
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 1GM IRON/20ML (50MG IRON/ML)
Approval Date : 2021-04-28
Application Number : 203565
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : INJECTAFER
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 100MG IRON/2ML (50MG IRON/ML)
Approval Date : 2022-02-04
Application Number : 203565
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Regulatory Info :
Registration Country : Italy
Brand Name : Ferinject
Dosage Form : Ferric Carbossimaltosio 50Mg/Ml 10Ml 1 Units Parenteral Use
Dosage Strength : 1 vial EV 10 ml 50 mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Ferinject
Dosage Form : Ferric Carbossimaltosio 50Mg/Ml 2Ml 5 Units Parenteral Use
Dosage Strength : 5 VIALS EV 2 ml 50 mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Australia
Brand Name : Ferinject
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Ferinject
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Ferinject
Dosage Form : INJ
Dosage Strength : 50mg/ml
Packaging : 10X1mg/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Under De...
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 50MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Under De...
Registration Country : India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Packaging :
Regulatory Info : Lead Market Dossiers- Under De...
Dosage : Injection
Dosage Strength : 50MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : USA
Registration Country : Greece
Brand Name :
Dosage Form : Solution for Injection...
Dosage Strength : 100MG/2ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : USA
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging :
Regulatory Info : USA
Dosage : Solution for Injection...
Dosage Strength : 100MG/2ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : USA
Registration Country : Greece
Brand Name :
Dosage Form : Solution for Injection...
Dosage Strength : 500MG/10ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : USA
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging :
Regulatory Info : USA
Dosage : Solution for Injection...
Dosage Strength : 500MG/10ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : USA
Registration Country : Greece
Brand Name :
Dosage Form : Solution for Injection...
Dosage Strength : 750MG/15ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : USA
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging :
Regulatory Info : USA
Dosage : Solution for Injection...
Dosage Strength : 750MG/15ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : USA
Registration Country : Greece
Brand Name :
Dosage Form : Solution for Injection...
Dosage Strength : 1000MG/20ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : USA
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging :
Regulatory Info : USA
Dosage : Solution for Injection...
Dosage Strength : 1000MG/20ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Vial
Dosage Strength : 50MG/ML
Packaging : 10 ml, 15 ml
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging : 10 ml, 15 ml
Regulatory Info :
Dosage : Vial
Dosage Strength : 50MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 50MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 50MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 50MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 50MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 50MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 50MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 50MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 50MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions
Global Sales Information
Dosage Form : Ferric Carbossimaltosio 50Mg/Ml ...
Dosage Strength : 1 vial EV 10 ml 50 mg/ml
Price Per Pack (Euro) : 135.55
Published in :
Country : Italy
RX/OTC/DISCN : Class H
Dosage Form : Ferric Carbossimaltosio 50Mg/Ml ...
Dosage Strength : 5 VIALS EV 2 ml 50 mg/ml
Price Per Pack (Euro) : 135.55
Published in :
Country : Italy
RX/OTC/DISCN : Class H
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 410
2019 Revenue in Millions : 456
Growth (%) : -10
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 672
2020 Revenue in Millions : 407
Growth (%) : 78
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 404
2021 Revenue in Millions : 672
Growth (%) : -40
Main Therapeutic Indication : Hematology
Currency : USD
2023 Revenue in Millions : 340
2022 Revenue in Millions : 404
Growth (%) : -5
Main Therapeutic Indication : Blood Disorders
Currency : USD
2017 Revenue in Millions : 214
2016 Revenue in Millions : 291
Growth (%) : -27
Main Therapeutic Indication : Blood Disorders
Currency : USD
2018 Revenue in Millions : 387
2017 Revenue in Millions : 200
Growth (%) : 93%
Main Therapeutic Indication : Hematology
Currency : USD
2019 Revenue in Millions : 452
2018 Revenue in Millions : 400
Growth (%) : 13
Market Place
Reply
20 Jul 2024
Reply
28 Jul 2023
Reply
19 Apr 2023
Reply
01 Jul 2022
Reply
21 Jun 2022
Reply
01 Apr 2022
Reply
19 Feb 2022
Reply
08 Jan 2022
Reply
31 Dec 2021
Reply
05 Jul 2023
Reply
28 Mar 2023
Reply
25 Sep 2020
Reply
30 Oct 2018
Reply
27 Sep 2018
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?